<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087733</url>
  </required_header>
  <id_info>
    <org_study_id>0003-08-2018</org_study_id>
    <nct_id>NCT04087733</nct_id>
  </id_info>
  <brief_title>Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery</brief_title>
  <official_title>Effectiveness of Liposomial Ozonized-Oil on Ocular Microbial Flora Before Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Molise</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Oftalmico, Torino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Fatebenefratelli e Oftalmico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Policlinico San Matteo Pavia Fondazione IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Borgo Trento - Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>S.Eugenio Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Mediterranea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Medico Oculistico ALSO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniche Humanitas Gavazzeni</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ISS Istituto per la Sicurezza Sociale, San Marino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Carlo di Nancy, Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro oftalmologico LASERVISTA, Caserta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Casa di cura GEPOS, Telese</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Casa Sollievo della Sofferenza IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria Consorziale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale generale regionale F. Miulli, Acquaviva delle Fonti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedali Riuniti, Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Santa Marta e Santa Venera, Acireale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Lentini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Molise</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the antimicrobial efficacy of a liposomal ozone-based solution (OZODROP®) , vs
      placebo in 200 patients undergoing cataract surgery by phacoemulsification .

      The clinical trial will last 3 days of treatment per patient. The conjunctival swab will be
      taken for each of the two eyes (in treatment and control) at T0 (before starting the
      treatment - 3 days before the cataract surgery) and at T3 (after 3 days of treatment -
      immediately before the cataract surgery). The last OZODROP instillation will take place 10
      minutes before taking the sample.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to assess the efficacy of a liposomal ozone-based solution (OZODROP®)
      in the preparation of the patient for cataract surgery, by evaluating the reduction of
      bacterial colonization of the conjunctiva.

      The study will be carried out at 20 surgical centers located throughout the national
      territory and will be conducted in accordance with the recommendations of Italian ethics
      committees.

      An informed consent will be provided to all study participants. 400 eyes of 200 patients
      undergoing cataract surgery by phacoemulsification will be included in the study. The
      clinical sample is divided into two groups, study group which will include treated and (GS)
      and control group (GC) eyes. The study group will be treated with OZODROP®, an isotonic
      ophthalmic solution composed of 0.5% ozonized oil in liposomes and hypromellose, while the GC
      will not be treated.

      At the time of recruitment, all eyes will undergo a complete examination, as usual, and the
      patient enrolled in the study will be shown how to proceed.

      The study includes 2 times, (T0) and (T3), equal for both groups in the study. 3 days before
      the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in
      the study, one in the eye to be operated and one in the control eye, who will be kept at a
      controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than,
      starting on the day of collection, the patients will instill the OZODROP® eye drops in the
      eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00,
      h21: 00), while the untreated contralateral eye will serve as a control.Immediately before
      the cataract surgery (T3), the patients enrolled in the study will again receive two
      conjunctival swabs, one in the eye to be operated and one in the control eye. The last
      OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the
      microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the
      Microbiology laboratory. The reduction of conjunctival microbial flora, expressed as CFU,
      will be evaluated.

      Through the analysis of the parameters in the study, a significant reduction in the microbial
      flora of the conjunctiva is expected in patients undergoing treatment with OZODROP®.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>GROUP / TREATED EYE (OZODROP® ): OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
GROUP / CONTROL EYE: No treatment. As a check you will use the contralateral eye that will not have to undergo cataract surgery.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of conjunctival bacterial load assessed by CFU (Colony Forming Units) using Ozodrop in 200 patients before cataract surgery</measure>
    <time_frame>3 days</time_frame>
    <description>Reduction/eradication of conjunctival bacterial load in patients treated with ozodrop for three days before undergoing cataract surgery.
For the microbiological evaluation, the conjunctival swabs taken at T0 (before starting OZODROP instillation) and T3 (after instilling OZODROP 4 times/day for three days) will be sent to the Microbiology laboratory to be seeded, enriched and then isolated the different species under examination by suitable selective media. The different samples will be analyzed according to the routine methods used in microbiology. The untreated contralateral eye will serve as a control.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ocular Infections</condition>
  <arm_group>
    <arm_group_label>GROUP / TREATED EYE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP / CONTROL EYE</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZODROP</intervention_name>
    <description>3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the untreated contralateral eye will serve as a control.Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory</description>
    <arm_group_label>GROUP / TREATED EYE</arm_group_label>
    <other_name>liposomal ozone-based solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years

          2. Patients eligible for cataract surgery

          3. Willingness to participate in the study following the indications

        Exclusion Criteria:

          1. Use of topical and / or systemic antibiotics and other topical antiseptics during the
             study

          2. Presence of topical ocular therapies that cannot be suspended for the entire duration
             of the study

          3. Ongoing ocular or systemic inflammatory or infectious processes

          4. Hypersensitivity to the constituents of the preparation in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Costagliola</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Molise</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Costagliola</last_name>
    <phone>08744092269</phone>
    <email>ciro.costagliola@unimol.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Molise</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costagliola Ciro</last_name>
      <phone>08744092269</phone>
      <email>ciro.costagliola@unimol.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28458509</url>
    <description>Reduction in bacterial load using hypochlorous acid hygiene solution on ocular skin.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27698616</url>
    <description>Human Microbiota and Ophthalmic Disease.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/26947261</url>
    <description>Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis</description>
  </link>
  <link>
    <url>https://www.escrs.org/</url>
    <description>escrs guidelines</description>
  </link>
  <link>
    <url>https://www.sedesoi.com/linee_guida.php</url>
    <description>soi guidelines</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20970112</url>
    <description>Reduction of anterior chamber contamination rate after cataract surgery by intraoperative surface irrigation with 0.25% povidone-iodine.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25485065</url>
    <description>Sub-Conjunctival Injection of Antibiotics vs. Povidone-Iodine Drop on Bacterial Colonies in Phacoemulsification Cataract Surgery.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26287981</url>
    <description>Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25230910</url>
    <description>Evaluation of corneal damage caused by iodine preparations using human corneal epithelial cells.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/28609415</url>
    <description>Effect of Povidone Iodine 5% on the Cornea, Vision, and Subjective Comfort.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/15232471</url>
    <description>Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/15030817</url>
    <description>Effect of prophylactic antibiotics on antimicrobial resistance of viridans streptococci in the normal flora of cataract surgery patients.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19969216</url>
    <description>Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/11168731</url>
    <description>Antibacterial activity of ozonized sunflower oil (Oleozon).</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21134039</url>
    <description>Ozonated sesame oil enhances cutaneous wound healing in SKH1 mice.</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

